Balance Sheet
Liabilities and Shareholders Equity
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Cash & Equivalents (2019 - 2025)

Benitec Biopharma (BNTC) has disclosed Cash & Equivalents for 7 consecutive years, with $103.6 million as the latest value for Q1 2025.

  • Quarterly Cash & Equivalents changed N/A to $103.6 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $103.6 million through Mar 2025, changed N/A year-over-year, with the annual reading at $50.9 million for FY2024, 1953.53% up from the prior year.
  • Cash & Equivalents hit $103.6 million in Q1 2025 for Benitec Biopharma, up from $78.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $103.6 million in Q1 2025 to a low of $2.5 million in Q2 2023.
  • Historically, Cash & Equivalents has averaged $28.5 million across 5 years, with a median of $16.1 million in 2021.
  • Biggest five-year swings in Cash & Equivalents: tumbled 79.45% in 2022 and later skyrocketed 1953.53% in 2024.
  • Year by year, Cash & Equivalents stood at $12.3 million in 2021, then decreased by 14.83% to $10.5 million in 2022, then surged by 94.04% to $20.4 million in 2023, then skyrocketed by 284.23% to $78.3 million in 2024, then soared by 32.32% to $103.6 million in 2025.
  • Business Quant data shows Cash & Equivalents for BNTC at $103.6 million in Q1 2025, $78.3 million in Q4 2024, and $67.8 million in Q3 2024.